Thrombospondin-1 and L-selectin Are Associated with Silent Cerebral Infarct in Children with Sickle Cell Anaemia

Overview

Journal Br J Haematol

Specialty Hematology

Date 2013 May 16

PMID 23672305

Citations 9

Authors

Lisa M Faulcon

Zongming Fu

Pratima Dulloor

Emily Barron-Casella

William Savage

Jacky M Jennings

Jennifer E Van Eyk

Michael DeBaun

James F Casella

Allen Everett

Affiliations

Soon will be listed here.

Citing Articles

Novel CSF biomarkers for diagnosis and integrated analysis of neuropsychiatric systemic lupus erythematosus: based on antibody profiling.

Ni J, Chen C, Wang S, Liu X, Tan L, Lu L Arthritis Res Ther. 2023; 25(1):165.

PMID: 37684700 PMC: 10486090. DOI: 10.1186/s13075-023-03146-z.

Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Lance E, Faulcon L, Fu Z, Yang J, Whyte-Stewart D, Strouse J Proteomics Clin Appl. 2021; 15(5):e2100003.

PMID: 33915030 PMC: 8666096. DOI: 10.1002/prca.202100003.

Thrombospondin-1/CD47 signaling modulates transmembrane cation conductance, survival, and deformability of human red blood cells.

Bissinger R, Petkova-Kirova P, Mykhailova O, Oldenborg P, Novikova E, Donkor D Cell Commun Signal. 2020; 18(1):155.

PMID: 32948210 PMC: 7502024. DOI: 10.1186/s12964-020-00651-5.

Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction.

Tewari S, Renney G, Brewin J, Gardner K, Kirkham F, Inusa B Haematologica. 2018; 103(7):1136-1142.

PMID: 29545349 PMC: 6029528. DOI: 10.3324/haematol.2018.187815.

Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Roberts D, Kaur S, Isenberg J Antioxid Redox Signal. 2017; 27(12):874-911.

PMID: 28712304 PMC: 5653149. DOI: 10.1089/ars.2017.7140.

References

Savage W, Barron-Casella E, Fu Z, Dulloor P, Williams L, Crain B . Plasma glial fibrillary acidic protein levels in children with sickle cell disease. Am J Hematol. 2011; 86(5):427-9. PMC: 3870012. DOI: 10.1002/ajh.21995. View

Quinn C, McKinstry R, Dowling M, Ball W, Kraut M, Casella J . Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2012; 70(1):58-65. PMC: 3677221. DOI: 10.1001/jamaneurol.2013.576. View

Kwiatkowski J, Zimmerman R, Pollock A, Seto W, Smith-Whitley K, Shults J . Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009; 146(3):300-5. PMC: 2793684. DOI: 10.1111/j.1365-2141.2009.07753.x. View

Kato G, Gladwin M, Steinberg M . Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2006; 21(1):37-47. PMC: 2048670. DOI: 10.1016/j.blre.2006.07.001. View

Coppinger J, OConnor R, Wynne K, Flanagan M, Sullivan M, Maguire P . Moderation of the platelet releasate response by aspirin. Blood. 2007; 109(11):4786-92. DOI: 10.1182/blood-2006-07-038539. View

Hillery C, Du M, Wang W, Scott J . Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000; 109(2):322-7. DOI: 10.1046/j.1365-2141.2000.02040.x. View

DeBaun M, Sarnaik S, Rodeghier M, Minniti C, Howard T, Iyer R . Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2011; 119(16):3684-90. PMC: 3335377. DOI: 10.1182/blood-2011-05-349621. View

Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I . Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2010; 117(4):1130-40. DOI: 10.1182/blood-2010-06-293514. View

Quinn C, Sargent J . Daytime steady-state haemoglobin desaturation is a risk factor for overt stroke in children with sickle cell anaemia. Br J Haematol. 2007; 140(3):336-9. PMC: 2562641. DOI: 10.1111/j.1365-2141.2007.06927.x. View

10.

Casella J, King A, Barton B, White D, Noetzel M, Ichord R . Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010; 27(2):69-89. PMC: 5572477. DOI: 10.3109/08880010903360367. View